PT -期刊文章盟索尼娅·吉尔AU - Hsiangkuo元盟-迈克尔·斯珀林AU -斯科特·明茨AU -克里斯托弗•斯基德莫尔盟Maromi Nei TI - VNS治疗与中断VNS治疗:长期发作的结果(p5.5 - 028) DP - 2019年4月09年TA -神经病学第六PG - p5.5 - 028 - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_supplement/p5.5 028. - 028.短4100 - htt首页p://www.ez-admanager.com/content/92/15_supplement/p5.5 - -全所以Neurology2019 4月09年;92 AB -目的:比较长期的癫痫患者(pts)(深圳)控制持续迷走神经的神经刺激(VNS)与那些接受停止。背景:长期接受随访(f / u)研究显示进步的改进,但受限于缺乏比较组。本研究相比长期sz控制在分继续刺激迷走神经刺激法(“VNS-on”)给那些接受了VNS然后停止治疗(“VNS-off”)。有更大的问题:pts与长期VNS sz减少比那些停止接受吗?设计/方法:与VNS治疗难治性癫痫分≥3年(f / u≥2年之后VNS中止VNS-off)明确基线(pre-VNS)和最后一个f / u sz频率都包括在内。分与脑部手术& lt; 3岁后迷走神经刺激法排除;仅在f / u脑部手术之前,如果执行,包括在内。我们评估和比较1)分率≥50%深圳减少应答率(50%),和2)深圳的变化频率f / u终于与基线相比VNS-on VNS-off分。结果:49分包括:33 VNS-on 16 VNS-off。VNS-on分治疗116.6±43个月。VNS-off pts VNS治疗78±37个月,停止治疗,然后95.63±38个月额外的后续。 50% responder rates between groups (VNS-on: 54.5%; VNS-off: 50%, p=NS) were similar. However, VNS-on pts had significant reduction in sz frequency at last f/u compared with baseline (−12.7 sz/month± 34.1, p = 0.04) compared with VNS-off pts both right before VNS was discontinued (−2.8 sz/month ± 18.5, p = 0.55) and last f/u (−4.4 sz/month ± 14.7, p = 0.25), though effect size was small (0.28).Conclusions: Pts with long-term VNS therapy and those who discontinued therapy had similar long-term 50% responder rates. However, pts with long-term VNS treatment may experience greater magnitude of sz reduction. Pts with poor VNS response may be more refractory. Larger confirmatory studies are needed.Disclosure: Dr. Gill has nothing to disclose. Dr. Yuan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Supernus. Dr. Sperling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Medtronic. Dr. Sperling has received research support from Eisai, Medtronic, Neurelis, Pfizer, SK Life Science, Takeda, Sunovion, UCB Pharma and Upsher-Smith. Dr. Mintzer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, UCB, Abbvie,Greenwich Laboratories. Dr. Mintzer has received research support from UCB. Dr. Skidmore has received research support from Neuropace. Dr. Nei has nothing to disclose.